SNRE Projected Dividend Yield

ADR Ser A/Sunrise Communications AG ( NASDAQ : SNRE )

Sorrento Therapeutics, together with its subsidiaries, is a clinical stage and commercial biopharmaceutical company developing a portfolio of treatments for three primary therapeutic areas: cancer, infectious disease and pain. Co. is focused on transforming science into Saving Life Medicines™ by developing product programs into focused commercial entities, like Scilex Holding Company (Scilex Holding). Co.'s proprietary fully human G-MAB™ antibody library and ACEA small molecule library are the engines driving a pipeline of solutions for cancer. Scilex Holding's main product, ZTlido®, has been launched as a prescription lidocaine topical product.

10 YEAR PERFORMANCE RESULTS